Table 1 – Types of vertigo (non-exhaustive list)[/caption]
Vomiting
In older people, dizziness significantly increases the risk of falls.7 Implementing appropriate interventions to address modifiable risk factors such as dizziness is of paramount importance. In cases of drug-induced dizziness, deprescribing can be considered if the medicine can be safely reduced, discontinued or substituted to prevent inappropriate prescribing cascades of potentially inappropriate medicines (PIM), especially in the context of older people.29
A national education program for pharmacists funded by the Australian Government under the Quality Use of Diagnostics, Therapeutics and Pathology program.[/caption]
The hypothalamus houses neurons that produce neuropeptides called orexin A and B, which were discovered in 1998, and represent one of the most exciting discoveries in sleep medicine.5,13–15 Orexin-producing neurons help us stay awake and alert, especially when we really need to focus, which is critical for survival.5,14 These neurons reach out to many brain areas that use other wakefulness messengers such as acetylcholine, dopamine, histamine, serotonin and noradrenaline. These areas ‘talk back’ to the hypothalamus, to further boost wakefulness signals.5 Similarly, the thalamus is an important region that also serves to relay wakefulness signals from the RAS.5
Another dual orexin receptor antagonist (DORA), vornorexant*, is under development and currently undergoing clinical trials.28 
Other medicines such as dimdazenil* (partial positive allosteric modulator at GABAA specific to alpha-1 and alpha-5 GABAA receptor subtypes)41 and zuranolone* (positive allosteric modulator for GABAA) have also been tested, with positive outcomes in trials. Zuranolone* is marketed overseas specifically for postnatal depression, but clinical trials for its use in insomnia are ongoing.40
Kristy Carter (she/her)
Louise Edwards (she/her) Pharmacist prescribing is a positive move
Evaluation overseas has found pharmacist prescribing to be safe, clinically appropriate and well-received by patients.
Pharmacy groups have long called for changes to allow pharmacists...
E-cigarettes warning after link with pulmonary illness in US
A new statement on e-cigarettes has been issued by the Australian Government Department of Health.
The Australian Government Department of Health has issued a new...
General practice opportunities for pharmacists
Pharmacists considering work in the general practice space now have two enablers – the Workforce Incentive Program (WIP) eligibility, which came into effect on...
Management of apathy in patients with Alzheimer’s disease
People diagnosed with Alzheimer’s disease often experience symptoms of apathy, which can be treated by pharmacological and behavioural interventions.
The purpose of this evidence...
DAA program to be expanded in community pharmacies
The Dose Administration Aids (DAA) program will be available to 70,000 more patients each year through community pharmacies, with the Federal Government announcing increased...
Medication adherence through community pharmacy intervention
Community pharmacist-led interventions have been shown to improve adherence and health outcomes for patients with chronic diseases but a number of barriers remain.
Researchers from...
